DAX24.226 +0,8%ESt505.415 +0,4%Top 10 Crypto14,71 +2,2%Dow42.344 +1,8%Nas19.199 +2,5%Bitcoin96.137 ±0,0%Euro1,1323 -0,1%Öl64,37 +0,1%Gold3.306 +0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 RENK RENK73 NVIDIA 918422 BYD A0M4W9 Tesla A1CX3T HENSOLDT HAG000 Siemens Energy ENER6Y thyssenkrupp 750000 Lufthansa 823212 Bayer BAY001 Deutsche Bank 514000 Infineon 623100 Mercedes-Benz Group (ex Daimler) 710000 BASF BASF11 Allianz 840400
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX nach Hoch über 24.300 Punkten mit Rekordschluss -- US-Handel endet mit Gewinnen -- BofA warnt vor NVIDIA-Ausblick -- D-Wave-Manager verkaufen Aktien -- Tesla, Siemens Energy, Rheinmetall im Fokus
Top News
Diese Werte hat Investoren-Legende Jeremy Grantham im ersten Quartal 2025 im Depot Diese Werte hat Investoren-Legende Jeremy Grantham im ersten Quartal 2025 im Depot
BYD bringt günstige Elektro-Limousine auf den Markt - Kampfansage an Tesla? BYD bringt günstige Elektro-Limousine auf den Markt - Kampfansage an Tesla?
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Volatile Kryptomärkte? Jetzt mit Krypto-CFD-Brokern wie eToro gezielt auf Marktchancen reagieren. Zu unserem Vergleich

Orexo (spons. ADRs) Aktie

Handeln
1,48 USD -0,38 USD -20,27 %
NASO
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Smartphone
ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS68616W1027

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolORXOY

Orexo (spons. ADRs) Aktien News

DatumMeistgelesen
PR NewswireOrexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology
PR NewswireOrexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology
PR NewswireOrexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis
PR NewswireOrexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis
PR NewswireOrexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology
PR NewswireOrexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology
PR NewswireOrexo initiates new study of OX640 in participants with allergic rhinitis
PR NewswireOrexo initiates new study of OX640 in participants with allergic rhinitis
PR NewswireOrexo Interim Report Q3 2024
PR NewswireOrexo Interim Report Q3 2024
PR NewswireOrexo´s Nomination Committee for the Annual General Meeting 2025
PR NewswireOrexo´s Nomination Committee for the Annual General Meeting 2025
PR NewswireOrexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024
PR NewswireOrexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024
PR NewswireOrexo Q2 2024 Interim Report
PR NewswireOrexo Q2 2024 Interim Report
PR NewswireOrexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose
PR NewswireOrexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose
PR NewswireOrexo AB´s sustainability work ranked among top 5% by EcoVadis
PR NewswireOrexo AB´s sustainability work ranked among top 5% by EcoVadis
PR NewswireOrexo: invitation to presentation of the Q2 2024 Interim Report
PR NewswireOrexo: invitation to presentation of the Q2 2024 Interim Report
PR NewswireOrexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
PR NewswireOrexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
PR NewswireOrexo Q1 2024 Interim Report
PR NewswireOrexo Q1 2024 Interim Report
PR NewswireReport from Orexo AB's annual general meeting, 26 April 2024
PR NewswireReport from Orexo AB's annual general meeting, 26 April 2024
PR NewswireOrexo extends patent protection for its nasal epinephrine powder product OX640 in the US
PR NewswireOrexo extends patent protection for its nasal epinephrine powder product OX640 in the US
PR NewswireOrexo announces that the condition for early redemption of its existing bonds has been fulfilled
PR NewswireOrexo announces that the condition for early redemption of its existing bonds has been fulfilled
PR NewswireOrexo publishes the Annual and Sustainability Report for 2023
PR NewswireOrexo publishes the Annual and Sustainability Report for 2023
PR NewswireCorrection: Notice of Annual General Meeting of Orexo
PR NewswireCorrection: Notice of Annual General Meeting of Orexo
PR NewswireNotice of Annual General Meeting of Orexo
PR NewswireNotice of Annual General Meeting of Orexo
PR NewswireOrexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds
PR NewswireOrexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds
Wer­bung

Orexo (spons. ADRs) News

Orexo (spons. ADRs) News: auf dieser Seite finden Sie alle Orexo (spons. ADRs) News und Nachrichten zur Orexo (spons. ADRs) Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Orexo (spons. ADRs) News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Orexo (spons. ADRs) News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.